Jasper Therapeutics (NASDAQ:JSPR) Earns Market Outperform Rating from JMP Securities

Jasper Therapeutics (NASDAQ:JSPR)‘s stock had its “market outperform” rating reiterated by stock analysts at JMP Securities in a report released on Monday,Benzinga reports. They presently have a $70.00 price objective on the stock. JMP Securities’ target price would suggest a potential upside of 295.26% from the company’s previous close.

JSPR has been the topic of a number of other reports. Cantor Fitzgerald restated an “overweight” rating on shares of Jasper Therapeutics in a research report on Monday, September 9th. BMO Capital Markets assumed coverage on Jasper Therapeutics in a report on Friday, December 6th. They issued an “outperform” rating and a $63.00 price target for the company. Royal Bank of Canada reissued an “outperform” rating and set a $68.00 price objective on shares of Jasper Therapeutics in a report on Monday, December 23rd. Finally, HC Wainwright restated a “buy” rating and issued a $65.00 price objective on shares of Jasper Therapeutics in a research report on Thursday, October 24th. Ten research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Jasper Therapeutics currently has a consensus rating of “Buy” and an average target price of $73.38.

Jasper Therapeutics Stock Down 15.1 %

NASDAQ:JSPR opened at $17.71 on Monday. The firm has a market cap of $265.67 million, a PE ratio of -3.74 and a beta of 2.18. Jasper Therapeutics has a 12 month low of $6.61 and a 12 month high of $31.01. The company’s 50-day moving average price is $21.95 and its two-hundred day moving average price is $20.46.

Institutional Trading of Jasper Therapeutics

A number of institutional investors have recently bought and sold shares of JSPR. JPMorgan Chase & Co. lifted its stake in shares of Jasper Therapeutics by 239.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 16,391 shares of the company’s stock valued at $308,000 after purchasing an additional 11,567 shares during the period. Barclays PLC lifted its stake in Jasper Therapeutics by 320.7% in the third quarter. Barclays PLC now owns 16,146 shares of the company’s stock valued at $304,000 after buying an additional 12,308 shares during the period. Jane Street Group LLC bought a new position in Jasper Therapeutics during the third quarter worth about $251,000. Wellington Management Group LLP acquired a new position in shares of Jasper Therapeutics during the 3rd quarter worth about $447,000. Finally, State Street Corp increased its stake in shares of Jasper Therapeutics by 12.3% in the 3rd quarter. State Street Corp now owns 214,883 shares of the company’s stock valued at $4,042,000 after acquiring an additional 23,564 shares during the last quarter. Institutional investors and hedge funds own 79.85% of the company’s stock.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.